IDEX (IEX) Earnings Date & Reports

Key Takeaways

• IDEX reported record third-quarter net sales of $951.7 million, up 8% from $878.7 million a year earlier.
• Adjusted diluted earnings per share (EPS, or profit allocated to each common share) came in at $2.33, ahead of the consensus estimate of roughly $2.23 to $2.24.
• Organic sales grew 8%, and total orders rose 13% year over year to nearly $1 billion, keeping book-to-bill above 1.0 times.
• Management raised its full-year 2026 outlook, citing broad-based momentum in data center, semiconductor, and space and defense markets.
• Adjusted gross margin expanded 70 basis points to 45.2%, while adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin rose 50 basis points to 27.8%.
• Free cash flow reached $214 million, up 14% year over year, representing 124% conversion of net income.
• For more detail on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages on the IEX ticker hub.
• You can also discover actionable trading ideas by exploring Trending AI Robots, which highlight AI-driven strategies across the market.

Earnings Context and Why It Matters

IDEX Corporation's third-quarter report matters because it tests whether the diversified engineered-products maker can sustain the demand inflection that began building through 2026. IDEX operates three segments — Health & Science Technologies (HST), Fluid & Metering Technologies (FMT), and Fire & Safety/Diversified Products (FSDP) — spanning end markets from life sciences and semiconductor manufacturing to water systems and aerospace. Investors watch this print closely for evidence that growth is broadening beyond the AI-driven data center and semiconductor categories that have powered recent quarters. With inflation still pressuring input costs, the report also serves as a key read on the company's ability to maintain price-cost discipline and expand margins, both central to its long-term investment thesis.

Reported Results

IDEX reported record third-quarter net sales of $951.7 million, up 8.3% from $878.7 million in the prior-year period, and above the analyst consensus of roughly $919 million to $935 million. Organic sales, which strip out the impact of acquisitions and currency, increased 8%. Net income attributable to IDEX rose to $144.1 million from $127.8 million, while diluted EPS reached $1.95, up from $1.70.

On an adjusted basis, which excludes certain items, diluted EPS climbed to $2.33 from $2.03 a year earlier, topping the consensus estimate of about $2.23 to $2.24 by roughly 4% to 4.5%. Adjusted EBITDA rose 10.4% to $264.8 million, with the adjusted EBITDA margin improving 50 basis points to 27.8%. Total orders reached $991.2 million, up 13% on an organic basis, and free cash flow of $214 million represented a 124% conversion rate. By segment, HST sales rose 14% to $433.5 million, FMT grew 3% to $327.9 million, and FSDP increased 5% to $191.5 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening, making it a practical resource for those who want to monitor names like IDEX alongside broader sector peers. Explore the AI Screener to build a watchlist aligned with your own criteria.

Market Reaction and Investor Sentiment

IDEX shares were little changed in the immediate aftermath of the report, holding near the $233 level, as the market weighed a clean beat against an already elevated valuation. The muted response partly reflects how much of the company's momentum had already been priced in, with results coming in ahead of guidance on every key measure yet failing to trigger a sharp repricing. Sentiment remained constructive, however, driven by record sales, better-than-expected adjusted EPS, and the raised full-year outlook. The quarter's standout was the HST segment, where organic orders jumped 21%, reinforcing confidence in the durability of AI-related demand. Persistent inflation and softer pockets in chemical valves and agriculture remain the primary factors tempering enthusiasm.

Forward Outlook and Key Factors to Monitor

IDEX raised its full-year 2026 guidance following the strong quarter, now projecting organic sales growth of 6.5% to 6.8% and adjusted diluted EPS of $8.91 to $8.96. The updated range signals management's confidence that momentum will carry into the fourth quarter and that growth is broadening beyond the advantaged markets that have led the expansion.

Investors should monitor several factors in the coming quarters. First, the pace of order activity in data center and semiconductor applications, where IDEX flagged expected timing-related swings between quarters, will be a key swing factor. Second, the trajectory of FMT's industrial businesses — including energy and agriculture — will indicate whether the early signs of stabilization translate into sustained recovery.

Margin execution also deserves close attention. Management said price-cost remained positive on a dollar basis and expects that trend to continue, but stubborn inflation and elevated energy costs remain a headwind. Finally, the integration and performance of Mott, the largest acquisition in the company's history, will be closely watched as IDEX works to lift that business toward segment-level margins. These catalysts, alongside broader industrial demand, will shape how investors assess the company's ability to sustain its current growth pace into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations